Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials

Marco Miroddi, Carmelo Sterrantino, Ilaria Simonelli, Giorgio Ciminata, Robert S. Phillips, Gioacchino Calapai

Research output: Contribution to journalArticlepeer-review

Abstract

The anti-Epidermal Growth Factor Receptor monoclonal antibodies (anti-EGFR MoAbs) are beneficial in the treatment of wild type (WT) KRAS colorectal cancer, but are burdened by serious toxicities. We conducted a systematic review and meta-analysis to determine incidence and relative risk (RR) of severe and life-threatening diarrhoea and mucositis in colorectal cancer patients and WT-KRAS subpopulation. PubMed and Embase were searched for trials comparing the same therapeutic regimens with or without anti-EGFR for colorectal cancer. Data on severe and life-threatening diarrhoea and mucositis were extracted from 18 studies involving 13,382 patients. Statistical analyses calculated incidence of AEs, RRs and 95% confidence intervals by using either random or fixed effects models. Patients receiving anti-EGFR MoAbs showed an increased risk of diarrhoea (RR: 1.66, CI 1.52-1.80) and mucositis (RR: 3.44, CI 2.66-4.44). The risk was similar among WT-KRAS patients. Prevention and risk reduction strategies of these AEs are mandatory to optimize clinical outcomes.

Original languageEnglish
Pages (from-to)355-371
Number of pages17
JournalCritical Reviews in Oncology/Hematology
Volume96
Issue number2
DOIs
Publication statusPublished - Oct 25 2014

Keywords

  • Adverse events
  • Anti-egfr monoclonal antibodies
  • Cetuximab
  • Colorectal cancer
  • Diarrhoea
  • Meta-analysis
  • Mucositis
  • Panitumumab
  • Pharmacovigilance
  • Systematic review

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials'. Together they form a unique fingerprint.

Cite this